{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T15:24:42Z","timestamp":1790522682179,"version":"4.1.0"},"reference-count":47,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","medical-hypotheses.com","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Medical Hypotheses"],"published-print":{"date-parts":[[2018,4]]},"DOI":"10.1016\/j.mehy.2018.02.019","type":"journal-article","created":{"date-parts":[[2018,2,21]],"date-time":"2018-02-21T02:16:28Z","timestamp":1519179388000},"page":"68-71","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["The role of trophoblastic epigenetic reprogrammation in benign tumor cells on malignant progression: A molecular hypothesis"],"prefix":"10.1016","volume":"113","author":[{"given":"Kevin","family":"Doello","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.mehy.2018.02.019_b0005","series-title":"Principles of molecular oncology","author":"Bronchud","year":"2008"},{"issue":"4238","key":"10.1016\/j.mehy.2018.02.019_b0010","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1016\/S0140-6736(01)34924-3","article-title":"Cancer genesis","volume":"164","author":"Beard","year":"1904","journal-title":"The Lancet"},{"issue":"2660","key":"10.1016\/j.mehy.2018.02.019_b0015","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1136\/bmj.2.2660.1678-b","article-title":"A biological view of the cancer cell","volume":"2","author":"Beard","year":"1911","journal-title":"BMJ"},{"issue":"2695","key":"10.1016\/j.mehy.2018.02.019_b0020","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1136\/bmj.2.2695.460","article-title":"The pancreatic treatment of cancer","volume":"2","author":"Beard","year":"1912","journal-title":"BMJ"},{"issue":"6","key":"10.1016\/j.mehy.2018.02.019_b0025","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1016\/j.celrep.2015.01.020","article-title":"HIGD1A regulates oxygen consumption, ROS production, and AMPK activity during glucose deprivation to modulate cell survival and tumor growth","volume":"10","author":"Ameri","year":"2015","journal-title":"Cell Rep"},{"issue":"4","key":"10.1016\/j.mehy.2018.02.019_b0030","doi-asserted-by":"crossref","first-page":"e1030537","DOI":"10.1080\/23723556.2015.1030537","article-title":"HIGD1A-mediated dormancy and tumor survival","volume":"2","author":"Ameri","year":"2015","journal-title":"Mol Cell Oncol"},{"key":"10.1016\/j.mehy.2018.02.019_b0035","series-title":"Placenta research methods and protocols","author":"Soares","year":"2005"},{"key":"10.1016\/j.mehy.2018.02.019_b0040","series-title":"The rise of fetal and neonatal physiology","author":"Longo","year":"2013"},{"issue":"2","key":"10.1016\/j.mehy.2018.02.019_b0045","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.jconrel.2012.04.038","article-title":"Macromolecular therapeutics in cancer treatment: the EPR effect and beyond","volume":"164","author":"Maeda","year":"2012","journal-title":"J Control Release"},{"key":"10.1016\/j.mehy.2018.02.019_b0050","doi-asserted-by":"crossref","unstructured":"McNanley T, Woods J. Placental physiology. The Global Library of Women\u2019s Medicine; 2008.","DOI":"10.3843\/GLOWM.10195"},{"key":"10.1016\/j.mehy.2018.02.019_b0055","unstructured":"Xuan YH. Expression of TGF-beta signaling proteins in normal placenta and gestational trophoblastic disease. \u2013 PubMed \u2013 NCBI [Internet]. Ncbi.nlm.nih.gov. [cited 29 July 2017]. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/17163397."},{"issue":"1","key":"10.1016\/j.mehy.2018.02.019_b0060","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1053\/plac.2002.0867","article-title":"Expression and activity of matrix metalloproteinase 2 and 9 in human trophoblasts","volume":"24","author":"Isaka","year":"2003","journal-title":"Placenta"},{"issue":"1","key":"10.1016\/j.mehy.2018.02.019_b0065","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1046\/j.1440-1711.1998.00717.x","article-title":"Tumour surveillance: missing peptides and MHC molecules","volume":"76","author":"Khanna","year":"1998","journal-title":"Immunol Cell Biol"},{"issue":"1","key":"10.1016\/j.mehy.2018.02.019_b0070","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/j.1423-0410.2011.01533.x","article-title":"Placental immunology and maternal alloimmune responses","volume":"102","author":"Kumpel","year":"2011","journal-title":"Vox Sang"},{"issue":"9","key":"10.1016\/j.mehy.2018.02.019_b0075","doi-asserted-by":"crossref","first-page":"4530","DOI":"10.4049\/jimmunol.1002031","article-title":"The link between the PDL1 costimulatory pathway and Th17 in fetomaternal tolerance","volume":"187","author":"D'Addio","year":"2011","journal-title":"J Immunol"},{"issue":"8","key":"10.1016\/j.mehy.2018.02.019_b0080","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/nrd4591","article-title":"Combination cancer immunotherapy and new immunomodulatory targets","volume":"14","author":"Mahoney","year":"2015","journal-title":"Nat Rev Drug Discovery"},{"issue":"1","key":"10.1016\/j.mehy.2018.02.019_b0085","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1053\/plac.2002.0898","article-title":"B7 family molecules: novel immunomodulators at the maternal-fetal interface","volume":"24","author":"Petroff","year":"2003","journal-title":"Placenta"},{"issue":"22","key":"10.1016\/j.mehy.2018.02.019_b0090","doi-asserted-by":"crossref","first-page":"10139","DOI":"10.1158\/0008-5472.CAN-05-0097","article-title":"HLA-G proteins in cancer: do they provide tumor cells with an escape mechanism?","volume":"65","author":"Rouas-Freiss","year":"2005","journal-title":"Cancer Res"},{"key":"10.1016\/j.mehy.2018.02.019_b0095","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2014\/359748","article-title":"The dual role of HLA-G in cancer","volume":"2014","author":"Rouas-Freiss","year":"2014","journal-title":"J Immunol Res"},{"key":"10.1016\/j.mehy.2018.02.019_b0100","first-page":"6","article-title":"HLA-G orchestrates the early interaction of human trophoblasts with the maternal niche","author":"Gregori","year":"2015","journal-title":"Front Immunol"},{"issue":"6","key":"10.1016\/j.mehy.2018.02.019_b0105","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.semcancer.2007.06.010","article-title":"HLA-G expression in malignant melanoma","volume":"17","author":"Rebmann","year":"2007","journal-title":"Semin Cancer Biol"},{"key":"10.1016\/j.mehy.2018.02.019_b0110","doi-asserted-by":"crossref","unstructured":"Tuncel T. Immunoregulatory function of HLA-G in gastric cancer. \u2013 PubMed \u2013 NCBI. [online] Ncbi.nlm.nih.gov. Available at: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/24460353 [Accessed 30 July 2017]. http:\/\/dx.doi.org\/10.7314\/APJCP.2013.14.12.7681.","DOI":"10.7314\/APJCP.2013.14.12.7681"},{"issue":"2","key":"10.1016\/j.mehy.2018.02.019_b0115","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1089\/cbr.2010.0924","article-title":"Human leukocyte antigen G expression in breast cancer: role in immunosuppression","volume":"26","author":"Elliott","year":"2011","journal-title":"Cancer Biother Radiopharm"},{"issue":"2\u20133","key":"10.1016\/j.mehy.2018.02.019_b0120","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1007\/s12026-011-8262-6","article-title":"Interleukin 10 in the tumor microenvironment: a target for anticancer immunotherapy","volume":"51","author":"Sato","year":"2011","journal-title":"Immunol Res"},{"issue":"4","key":"10.1016\/j.mehy.2018.02.019_b0125","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.4049\/jimmunol.1401536","article-title":"The human fetal placenta promotes tolerance against the semiallogeneic fetus by inducing regulatory T cells and homeostatic M2 macrophages","volume":"194","author":"Svensson-Arvelund","year":"2015","journal-title":"J Immunol"},{"key":"10.1016\/j.mehy.2018.02.019_b0130","doi-asserted-by":"crossref","unstructured":"Hu W. Tumor-associated macrophages in cancers. \u2013 PubMed \u2013 NCBI [Internet]. Ncbi.nlm.nih.gov [cited 30 July 2017]. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/26264497. http:\/\/dx.doi.org\/10.1007\/s12094-015-1373-0.","DOI":"10.1007\/s12094-015-1373-0"},{"key":"10.1016\/j.mehy.2018.02.019_b0135","unstructured":"Bennett WA. Expression and production of interleukin-10 by human trophoblast: relationship to pregnancy immunotolerance. \u2013 PubMed \u2013 NCBI [Internet]. Ncbi.nlm.nih.gov. [cited 30 July 2017]. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/10086069."},{"issue":"2","key":"10.1016\/j.mehy.2018.02.019_b0140","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1158\/2326-6066.CIR-14-0137","article-title":"Extensive profiling of the expression of the indoleamine 2,3-dioxygenase 1 protein in normal and tumoral human tissues","volume":"3","author":"Theate","year":"2014","journal-title":"Cancer Immunol Res"},{"issue":"4","key":"10.1016\/j.mehy.2018.02.019_b0145","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1007\/s13402-013-0134-8","article-title":"In vitro treatment of carcinoma cell lines with pancreatic (pro)enzymes suppresses the EMT programme and promotes cell differentiation","volume":"36","author":"Per\u00e1n","year":"2013","journal-title":"Cell Oncol"},{"key":"10.1016\/j.mehy.2018.02.019_b0150","unstructured":"Shvartsur A, Bonavida B. Trop2 and its overexpression in cancers: regulation and clinical\/therapeutic implications. \u2013 PubMed \u2013 NCBI [Internet]. Ncbi.nlm.nih.gov. [cited 30 July 2017]. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/26000093."},{"key":"10.1016\/j.mehy.2018.02.019_b0155","unstructured":"Genecards.org. [Internet]. [cited 30 July 2017]. Available from: http:\/\/www.genecards.org\/."},{"key":"10.1016\/j.mehy.2018.02.019_b0160","unstructured":"Proteinatlas.org. The Human Protein Atlas [Internet]. [cited 30 July 2017]. Available from: http:\/\/www.proteinatlas.org\/."},{"key":"10.1016\/j.mehy.2018.02.019_b0165","unstructured":"Neumann A. [Human placental alkaline phosphatase (hPLAP) is the most frequently elevated serum marker in testicular cancer]. \u2013 PubMed \u2013 NCBI [Internet]. Ncbi.nlm.nih.gov. [cited 30 July 2017]. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/21809268."},{"issue":"2","key":"10.1016\/j.mehy.2018.02.019_b0170","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1097\/DAD.0b013e318284a586","article-title":"Placental alkaline phosphatase positivity in metastatic melanoma","volume":"36","author":"Frieling","year":"2014","journal-title":"Am J Dermatopathol"},{"issue":"1","key":"10.1016\/j.mehy.2018.02.019_b0175","doi-asserted-by":"crossref","first-page":"86","DOI":"10.4161\/mabs.27230","article-title":"A human monoclonal antibody specific to placental alkaline phosphatase, a marker of ovarian cancer","volume":"6","author":"Ravenni","year":"2013","journal-title":"mAbs"},{"issue":"6","key":"10.1016\/j.mehy.2018.02.019_b0180","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1158\/0008-5472.CAN-12-3682","article-title":"Alkaline phosphatase ALPPL-2 is a novel pancreatic carcinoma-associated protein","volume":"73","author":"Dua","year":"2013","journal-title":"Cancer Res"},{"issue":"4","key":"10.1016\/j.mehy.2018.02.019_b0185","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1097\/MAJ.0b013e31818967a3","article-title":"Relationship between pregnancy-associated plasma protein-A and lung cancer","volume":"337","author":"Bulut","year":"2009","journal-title":"Am J Med Sci"},{"issue":"18","key":"10.1016\/j.mehy.2018.02.019_b0190","doi-asserted-by":"crossref","first-page":"15953","DOI":"10.18632\/oncotarget.3643","article-title":"Pregnancy associated plasma protein-A links pregnancy and melanoma progression by promoting cellular migration and invasion","volume":"6","author":"Prithviraj","year":"2015","journal-title":"Oncotarget"},{"issue":"4","key":"10.1016\/j.mehy.2018.02.019_b0195","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1158\/1535-7163.MCT-14-0880","article-title":"A novel neutralizing antibody targeting pregnancy-associated plasma protein-a inhibits ovarian cancer growth and ascites accumulation in patient mouse tumorgrafts","volume":"14","author":"Becker","year":"2015","journal-title":"Mol Cancer Ther"},{"issue":"3","key":"10.1016\/j.mehy.2018.02.019_b0200","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1016\/j.cellsig.2013.11.002","article-title":"Epigenetic and non-epigenetic regulation of syncytin-1 expression in human placenta and cancer tissues","volume":"26","author":"Huang","year":"2014","journal-title":"Cell Signal"},{"issue":"1","key":"10.1016\/j.mehy.2018.02.019_b0205","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s00109-006-0104-y","article-title":"Proliferation and cell\u2013cell fusion of endometrial carcinoma are induced by the human endogenous retroviral Syncytin-1 and regulated by TGF-\u03b2","volume":"85","author":"Strick","year":"2006","journal-title":"J Mol Med"},{"key":"10.1016\/j.mehy.2018.02.019_b0210","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1100\/tsw.2007.212","article-title":"Syncytin and cancer cell fusions","volume":"7","author":"Larsson","year":"2007","journal-title":"Scientific World J"},{"issue":"5","key":"10.1016\/j.mehy.2018.02.019_b0215","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/j.humpath.2006.10.018","article-title":"Prognostic role of syncytin expression in breast cancer","volume":"38","author":"Larsson","year":"2007","journal-title":"Hum Pathol"},{"issue":"8","key":"10.1016\/j.mehy.2018.02.019_b0220","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1089\/scd.2008.0338","article-title":"CD133 as a marker for cancer stem cells: progresses and concerns","volume":"18","author":"Wu","year":"2009","journal-title":"Stem Cells Dev"},{"issue":"3","key":"10.1016\/j.mehy.2018.02.019_b0225","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1002\/med.21297","article-title":"Sigma-2 receptor ligands and their perspectives in cancer diagnosis and therapy","volume":"34","author":"Huang","year":"2013","journal-title":"Med Res Rev"},{"issue":"1","key":"10.1016\/j.mehy.2018.02.019_b0230","doi-asserted-by":"crossref","first-page":"10","DOI":"10.3858\/emm.2012.44.1.023","article-title":"Role of placenta growth factor in cancer and inflammation","volume":"44","author":"Kim","year":"2011","journal-title":"Exp Mol Med"},{"key":"10.1016\/j.mehy.2018.02.019_b0235","unstructured":"Genetics Home Reference. Laron syndrome [Internet]. [cited 30 July 2017]. Available from: http:\/\/ghr.nlm.nih.gov\/condition\/laron-syndrome."}],"container-title":["Medical Hypotheses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0306987717309027?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0306987717309027?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,10,11]],"date-time":"2019-10-11T03:25:57Z","timestamp":1570764357000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0306987717309027"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4]]},"references-count":47,"alternative-id":["S0306987717309027"],"URL":"https:\/\/doi.org\/10.1016\/j.mehy.2018.02.019","relation":{},"ISSN":["0306-9877"],"issn-type":[{"value":"0306-9877","type":"print"}],"subject":[],"published":{"date-parts":[[2018,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The role of trophoblastic epigenetic reprogrammation in benign tumor cells on malignant progression: A molecular hypothesis","name":"articletitle","label":"Article Title"},{"value":"Medical Hypotheses","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mehy.2018.02.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}